deltatrials
Completed PHASE3 NCT00035451

Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.

Sponsor: Forest Laboratories

Conditions Atrial Fibrillation
Interventions Azimilide Dihydrochloride Placebo Sotalol
Updated 7 times since 2017 Last updated: Sep 30, 2011 Started: Feb 28, 2001 Primary completion: Jun 30, 2003 Completion: Jun 30, 2003

This PHASE3 trial investigates Atrial Fibrillation and is currently completed. Forest Laboratories leads this study, which shows 7 recorded versions since 2001 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Feb 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Forest Laboratories
Data source: Forest Laboratories

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aix-en-Provence, France, Alicante, Spain, Annaberg, Germany, Asti, Italy, Bad Nauheim, Germany, Bad Rothenfelde, Germany, Balatonfüred, Hungary, Barcelona, Spain, Bari, Italy, Basurto-Bilbao, Spain and 89 more location s